New IBD drug candidate passes first safety check in healthy volunteers
NCT ID NCT07616791
First seen Jun 06, 2026 · Last updated Jun 15, 2026 · Updated 1 time
Summary
This early-phase study tested the safety and tolerability of INT-210 capsules in 86 healthy adults aged 18-45. Researchers gave single and multiple doses, and also checked how food affects the drug. The goal was to gather safety data before testing in people with inflammatory bowel disease (IBD). Participants did not have IBD and received no direct treatment benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBD (INFLAMMATORY BOWEL DISEASE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Municipality - Beijing Municipality - No. 101, Luyuan East Road, Tongzhou District, Beijing
Beijing, China
Conditions
Explore the condition pages connected to this study.